Zürich (ots) - Was nervt Journalisten an Mediensprechern am meisten? Antwort: Wenn sie keine ehrlichen ...
Antisoma promotes Nick Adams to Director of Business Development
London, UK (ots) - Antisoma, (LSE: ASM) the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the promotion of Mr Nicholas Adams to Director of Business Development.
Nick will lead Antisoma's business development team, for which a key focus remains the acquisition of new products to add to Antisoma's pipeline. He has also been appointed to Antisoma's Executive Committee, the group responsible for the day to day running of Antisoma Research Ltd, the wholly owned subsidiary of Antisoma plc.
Nick had held the position of Business Development Manager at Antisoma since June 1999. In this role he negotiated a number of in-licensing deals and established significant development collaborations. He was also an important contributor to the negotiations leading to the formation of Antisoma's development and commercialisation alliance with Roche in November 2002.
Nick, 39, studied at the College of Law, London and holds a BSc (Hons) in Biology from the University of Hertfordshire. Prior to joining Antisoma he held R&D positions at Ciba-Geigy, Eisai Ltd and Cephalon Inc.
Nick replaces Bart Wuurman, who, after five years at Antisoma, will become Chief Executive Officer of De Novo Pharmaceuticals Ltd.
Glyn Edwards, Antisoma's CEO, said, "Nick brings invaluable expertise and experience to his new role as Director of Business Development and I welcome him to our senior team. I would also like to take this opportunity to thank Bart for his excellent contribution to the company, notably his leading role in creating our alliance with Roche."
Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. The Company fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma forms partnerships with pharmaceutical companies to bring its products to market. In November 2002, Antisoma signed a ground-breaking collaboration agreement with Roche to develop and commercialise products from Antisoma's pipeline. Please visit www.antisoma.com for further information.
This information is provided by RNS
The company news service from the London Stock Exchange
ots Originaltext: Antisoma
Head of Corporate Communications